دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 4,800,000 تومان- قیمت ویژه : 2,400,000تومان
پکیج دسترسی ۳ ماهه به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 93 ﺭﻭﺯ
- :
قیمت : 1,500,000 تومان- قیمت ویژه : 750,000تومان
پکیج دسترسی یکماهه به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 31 ﺭﻭﺯ
قیمت : 600,000 تومان- قیمت ویژه : 300,000تومان
For ovarian cancer PARPi maintenance therapy: more is better, right?
R.L.Coleman
Classification of atypical EGFR mutations in non-small-cell lung cancer
R.Rosell123A.F.Cardona4O.Arrieta5M.González-Cao2
Clinical trials for metastatic castrate-resistant prostate cancer—who is looking after the control patients? Questions for the future
L.C.Ardolino123R.Dear123A.J.Armstrong4S.Gillessen567A.M.Joshua1238
Alternative RNA splicing defects in pediatric cancers: new insights in tumorigenesis and potential therapeutic vulnerabilities
A.S.Venkataramany12K.M.Schieffer3K.Lee345C.E.Cottrell345P.Y.Wang46E.R.Mardis34T.P.Cripe467D.S.Chandler68
The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer
K.E.Francis12S.I.Kim3M.Friedlander45V.Gebski1I.Ray-Coquard67A.Clamp8R.T.Penson9A.Oza10T.Perri11T.Huzarski1213C.Martin-Lorente1415S.C.Cecere16N.Colombo17B.Ataseven1819K.Fujiwara20G.Sonke2122I.Vergote2324E.Pujade-Lauraine625…C.K.Lee12
Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM)
M.Janning1234J.Süptitz5C.Albers-Leischner4P.Delpy167A.Tufman8J.-L.Velthaus-Rusik4M.Reck9A.Jung1011D.Kauffmann-Guerrero8I.Bonzheim12S.Brändlein13H.-D.Hummel14M.Wiesweg15H.-U.Schildhaus16J.A.Stratmann17M.Sebastian17J.Alt18J.Buth19…GernotRohde
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study
H.S.Rugo1J.O’Shaughnessy2F.Boyle34M.Toi5R.Broom6I.Blancas78M.Gumus9T.Yamashita10Y.-H.Im11P.Rastogi12F.Zagouri13C.Song14M.Campone15B.San Antonio16A.Shahir16M.Hulstijn16J.Brown16A.Zimmermann16…S.M.Tolaney19
Tumor budding is an independent prognostic factor in stage III colon cancer patients: a post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR)
D.Basile123†C.Broudin4†J.F.Emile56A.Falcoz78F.Pagès9L.Mineur10J.Bennouna11C.Louvet12P.Artru13S.Fratte1415F.Ghiringhelli16T.André17V.Derangère1516D.Vernerey78J.Taieb1†M.Svrcek17†for PRODIGE investigators, GERCOR, Fédération Française de Cancerologie Digestive, and UNICANCER
Genetic variation within the human papillomavirus type 16 genome is associated with oropharyngeal cancer prognosis
K.A.Lang Kuhs12D.L.Faden34L.Chen5D.K.Smith6M.Pinheiro7C.B.Wood89S.Davis8M.Yeager710J.F.Boland710M.Cullen710M.Steinberg710S.Bass710X.Wang11P.Liu12M.Mehrad13T.Tucker1J.S.LewisJr813R.L.Ferris1415†L.Mirabello7â€
Inflammatory bowel disease and risk of adenocarcinoma and neuroendocrine tumors in the small bowel
J.Yu1†E.Refsum23†V.Perrin1‡L.M.Helsingen23‡P.Wieszczy234M.Løberg23M.Bretthauer23H.O.Adami13W.Ye15J.Blom6M.Kalager23
Risk of MDS/AML with the addition of neoadjuvant carboplatin to standard chemotherapy for triple-negative breast cancer
A.Okines1N.Turner12
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
G.F.Fleming1O.Pagani2M.M.Regan3B.A.Walley4P.A.Francis5
Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the die has not been cast
B.Tomasik1M.Bieńkowski2J.Jassem1
Improving at a nationwide level the management of patients with sarcomas with an expert network
J.-Y.Blay1N.Penel2F.Gouin1A.Le Cesne3M.Toulmonde4
Risk and severity of SARS-CoV-2 infection in breast cancer patients undergoing a structured infection screening program at the University and Hospital Trust of Verona
S.Zanelli1†E.Fiorio1†I.Zampiva12F.Zacchi1G.Borghesani1E.Giontella1V.Parolin1P.Biondani1S.Zuliani1M.V.Dieci34E.Mioranza3M.Zorzi5M.Conti6D.Gibellini7G.Verlato8M.Milella1
VP5-2022: Updated progression-free survival (PFS) and depth of response in IKEMA, a randomized phase III trial of isatuximab, carfilzomib and dexamethasone (Isa-Kd) vs Kd in relapsed multiple myeloma (MM)
P.Moreau1M.A.C.Dimopoulos2J.Mikhael3K.Yong4M.Capra5T.Facon6R.Hajek7I.Špi�ka8F.Casca9S.Mace10E.Singh11M-L.Risse12T.Martin13
Corrigendum to “Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up�: [Annals of Oncology 29 suppl. 4 (2018) v238–iv255]
A.Vogel1A.Cervantes2I.Chau3B.Daniele4J.M.Llovet567T.Meyer89J.-C.Nault10U.Neumann11J.Ricke12B.Sangro13P.Schirmacher14C.Verslype15C.J.Zech16D.Arnold17E.Martinelli18ESMO Guidelines Committee
Corrigendum to ‘128P Surgical management of lung metastases: A work-in-progress report from an international ESTS research group’ Annals of Oncology Volume 33 Supplement 2 (2022) S91-S92
E.Prisciandaro12L.Bertolaccini1D.van Raemdonck2J.Moons2P.De Leyn2H.Decaluwé2L.Spaggiari1L.J.Ceulemans2
Erratum to “Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust�: [Annals of Oncology 32 (2021) 1077–1082]
M.J.Piccart12K.Kalinsky3R.Gray4W.E.Barlow5C.Poncet6F.Cardoso7E.Winer8J.Sparano9
